A microfluidic diffraction device is developed for determination of CTC/bacteria from human whole blood with a home-constructed laser beam system. We design the optical structuretransfer the structure to transparent plastic substrate. The plastic diffraction die is modified with antibodies of the target to combine a fluidic system as a microfluidic diffraction chip. When human whole blood with CTCs/bacteria flows through the chip, the number of cells/bacteria can be obtained directly with label-free. The devices has been applied in clinical diagnosis of oesophagealendometrial cancer.

Cancer is the first leading cause of death in Taiwan. Targeted therapy allows the cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. This report contains two invention technologies which combined early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis)the treated with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA) to inhibit the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers.

This technology is used to reveal the immune profiling of the tumor microenvironment based on multi-color immunohistochemistry staining. Each immune cell type will be probed with different fluorophores,the density, as well as the location of each immune cell type on the tissue slides, will be disclosed using inForm software.